1
|
Mauro FR, Giannarelli D, Galluzzo C, Visentin A, Frustaci AM, Sportoletti P, Vitale C, Reda G, Gentile M, Levato L, Murru R, Armiento D, Ielo C, Maglione R, Crisanti E, Cipiciani A, Mattiello V, Gianfelici V, Barabino L, Amici R, Coscia M, Tedeschi A, Trentin L, Baroncelli S. P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, CENTRALIZED, MULTICENTER STUDY. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000845524.05971.e8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
2
|
Tam CSL, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss B, Moreno C, Szafer‐Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Ghia P, Wierda WG. CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL). Hematol Oncol 2021. [DOI: 10.1002/hon.32_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C. S. L Tam
- Peter MacCallum Cancer Center & St. Vincent's Hospital and the University of Melbourne Haematology and Disease Group, Melbourne VIC Australia
| | - J. N Allan
- Weill Cornell Medicine, Hematology/Oncology New York USA
| | - T Siddiqi
- City of Hope National Medical Center Hematology Duarte USA
| | - T. J Kipps
- UCSD Moores Cancer Center Chronic Lymphocytic Leukemia San Diego USA
| | - R Jacobs
- Levine Cancer Institute Hematology and Medical Oncology Charlotte USA
| | - S Opat
- Monash University, Clinical Haematology Clayton VIC Australia
| | - P. M Barr
- Wilmot Cancer Institute University of Rochester Medical Center Hematology/Oncology Rochester USA
| | - A Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Haematology Milan Italy
| | - L Trentin
- Hematology and Clinical Immunology Unit Department of Medicine University of Padova, Hematology Padova Italy
| | - R Bannerji
- Rutgers Cancer Institute of New Jersey Hematology/Oncology New Brunswick USA
| | - S Jackson
- Middlemore Hospital, Haematology Auckland New Zealand
| | - B Kuss
- Flinders University and Medical Centre Haemotology and Molecular Genetics, Bedford Park SA Australia
| | - C Moreno
- Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Hematology Barcelona Spain
| | - E Szafer‐Glusman
- Pharmacyclics LLC, an AbbVie Company, Translational Medicine Sunnyvale USA
| | - K Russell
- Pharmacyclics LLC, an AbbVie Company, Clinical Program Development Sunnyvale USA
| | - C Zhou
- Pharmacyclics LLC, an AbbVie Company, Biostatistics Sunnyvale USA
| | - J Ninomoto
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - J. P Dean
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - P Ghia
- ivision of Experimental Oncology Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele, Experimental Oncology Milan Italy
| | - W. G Wierda
- University of Texas MD Anderson Cancer Center Leukemia Houston USA
| |
Collapse
|
3
|
Gallamini A, Rambaldi A, Patti C, Romano A, Viviani S, Bolis S, Oppi S, Trentin L, Cantonetti M, Sorasio R, Gavarotti P, Gottardi D, Schiavotto C, Battistini R, Gini G, Ferreri A, Pavoni C, Bergesio F, Ficola U, Guerra L, Chauvie S. BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FIL HD0607 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.19_2879] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A Gallamini
- Antoine Lacassagne Cancer Center Research and Clinical Innovation Nice France
| | - A Rambaldi
- Ospedale Papa Giovanni XXIII Hematology Bergamo Italy
| | - C Patti
- Ospedali Riuniti di Palermo Hematology Palermo Italy
| | - A Romano
- Policlinico Universitario A. Ferrarotto Hematology Catania Italy
| | - S Viviani
- Istituto Europeo di Ematologia Hematology Milano Italy
| | - S Bolis
- Ospedale S. Gerardo Hematology Monza Italy
| | - S Oppi
- Ospedale Antonio Businco Hematology Cagliari Italy
| | - L Trentin
- Azienda Ospedaliera di Padova Hematology Padova Italy
| | | | - R Sorasio
- Ospedale S. Croce e Carle Hematology Cuneo Italy
| | - P Gavarotti
- Ospedale S. Giovanni Battista Hematology ‐ University Torino Italy
| | - D Gottardi
- Ospedale Mauriziano Hematology Torino Italy
| | | | - R Battistini
- Ospedale S. Camillo Forlanini Hematology Roma Italy
| | - G Gini
- Ospedali Riuniti di Ancona Hematology Ancona Italy
| | | | - C Pavoni
- Ospedale Papa Giovanni XXIII Hematology Bergamo Italy
| | - F Bergesio
- Ospedale S. Croce e Carle Medical Physics Cuneo Italy
| | - U Ficola
- Ospedale La Maddalena Nuclear Medicine Palermo Italy
| | - L Guerra
- Ospedale S. Gerardo Nuclear Medicine Monza Italy
| | - S Chauvie
- Ospedale S. Croce e Carle Medical Physics Cuneo Italy
| |
Collapse
|
4
|
Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. Ann Oncol 2019; 29:966-972. [PMID: 29365086 DOI: 10.1093/annonc/mdy021] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Beside patients requiring immediate treatment, others show an initial indolent phase followed by progression and others do not progress for decades. The latter two subgroups usually display mutated IGHV genes and a favorable FISH profile. Patients and methods Patients with absence of disease progression for over 10 years (10-34) from diagnosis were defined as ultra-stable CLL (US-CLL). Forty US-CLL underwent extensive characterization including whole exome sequencing (WES), ultra-deep sequencing and copy number aberration (CNA) analysis to define their unexplored genetic landscape. Microarray analysis, comparing US-CLL with non-US-CLL with similar immunogenetic features (mutated IGHV/favorable FISH), was also carried out to recognize US-CLL at diagnosis. Results WES was carried out in 20 US-CLL and 84 non-silent somatic mutations in 78 genes were found. When re-tested in a validation cohort of 20 further US-CLL, no recurrent lesion was identified. No clonal mutations of NOTCH1, BIRC3, SF3B1 and TP53 were found, including ATM and other potential progression driving mutations. CNA analysis identified 31 lesions, none with known poor prognostic impact. No novel recurrent lesion was identified: most cases showed no lesions (38%) or an isolated del(13q) (31%). The expression of 6 genes, selected from a gene expression profile analysis by microarray and quantified by droplet digital PCR on a cohort of 79 CLL (58 US-CLL and 21 non-US-CLL), allowed to build a decision-tree capable of recognizing at diagnosis US-CLL patients. Conclusions The genetic landscape of US-CLL is characterized by the absence of known unfavorable driver mutations/CNA and of novel recurrent genetic lesions. Among CLL patients with favorable immunogenetics, a decision-tree based on the expression of 6 genes may identify at diagnosis patients who are likely to maintain an indolent disease for decades.
Collapse
Affiliation(s)
- S Raponi
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - I Del Giudice
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Marinelli
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - J Wang
- Division of Life Science and Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong
| | - L Cafforio
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - C Ilari
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Messina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Bonina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Bordyuh
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - P Mariglia
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - N Peragine
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - F R Mauro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Chiaretti
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Molica
- Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - M Gentile
- Hematology Uni, Department of Hemato-Oncology, Ospedale Annunziata, Cosenza, Italy
| | - A Visentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - L Trentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - G M Rigolin
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - A Cuneo
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F Diop
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - D Rossi
- Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - R Foà
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
| |
Collapse
|
5
|
Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M, Oppi S, Viviani S, Bolis S, Trentin L, Gini G, Battistini R, Chauvie S, Bertolotti L, Pavoni C, Parvis G, Zanotti R, Gavarotti P, Cimminiello M, Schiavotto C, Viero P, Avigdor A, Tarella C, Rambaldi A. CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.105_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Gallamini
- Research & Clinical Innovation; Antoine Lacassagne Cancer Centre; Nice France
| | - A. Rossi
- Department of Oncology-Hematology; University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo Italy
| | - C. Patti
- Hematology; V. Cervello Hospital; Palermo Italy
| | - M. Picardi
- Hematology; Policlinico Federico II; Naples Italy
| | - A. Romano
- Hematology; Policlinico Vittorio Emanuele Hospital; Catania Italy
| | - M. Cantonetti
- Hematology; Policlinico Hospital Tor Vergata; Rome Italy
| | - S. Oppi
- Hematology; Businco Oncology Hospital; Cagliari Italy
| | - S. Viviani
- Hematology; National Institute of tumors; Milan Italy
| | - S. Bolis
- Hematology; S. Gerardo University Hospital; Monza Italy
| | | | - G. Gini
- Hematology; Ospedali Riuniti Le Torrette; Ancona Italy
| | - R. Battistini
- Hematology; S. Camillo Forlanini Hospital; Rome Italy
| | - S. Chauvie
- Medical Physics; S. Croce Hospital; Cuneo Italy
| | | | - C. Pavoni
- Department of Oncology-Hematology; University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo Italy
| | - G. Parvis
- Hematology; Mauriziano Hospital; Turin Italy
| | - R. Zanotti
- Hematology; Azienda Ospedaliera Universitaria Integrata; Verona Italy
| | - P. Gavarotti
- Hematology; University Hospital Città della salute; Turin Italy
| | | | | | - P. Viero
- Hematology; Dell'Angelo Hospital; Venice Italy
| | - A. Avigdor
- Hematolog and Bone Marrow Transplantation; Sheba Medical Center; Tel-Aviv Israel
| | - C. Tarella
- Hematology; European Institute of Oncology; Milan Italy
| | - A. Rambaldi
- Department of Oncology-Hematology; University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo Italy
| |
Collapse
|
6
|
Briani C, Visentin A, Salvalaggio A, Cacciavillani M, Trentin L. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy. Eur J Neurol 2018; 26:371-375. [PMID: 30315672 DOI: 10.1111/ene.13838] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Accepted: 10/08/2018] [Indexed: 12/30/2022]
Abstract
BACKGROUND AND PURPOSE Rituximab, a chimeric anti-CD20 monoclonal antibody, has been used in polyneuropathy associated with anti-myelin-associated glycoprotein (anti-MAG) antibody polyneuropathy with controversial results. Herein, two patients with anti-MAG antibody neuropathy and concurrent chronic lymphocytic leukemia (CLL) are reported, who dramatically responded to obinutuzumab, a novel glycoengineered humanized anti-CD20 monoclonal antibody. METHODS Patient 1 was an 82-year-old man with severe demyelinating sensory-motor neuropathy. He was wheelchair-bound, with loss of sensation up to the knees. He had a CLL, immunoglobulin M (IgM) lambda monoclonal gammopathy, with anti-MAG antibodies >70 000 Bühlmann titer units (BTU). Patient 2 was an 84-year-old woman with demyelinating neuropathy, paresthesias and gait instability. She had CLL and IgM kappa paraprotein with anti-MAG antibodies >70 000 BTU. Both patients were treated with obinutuzumab intravenously at 100 mg on day +1, 900 mg +2, then at 1000 mg on days 8 and 15 of cycle 1 and day 1 of cycles 2-6; chlorambucil was given orally at 0.5 mg/kg on days 1 and 15 of cycles 1-6. RESULTS Patient 1 at cycle 6 was able to stand, gait was possible with monolateral support, hypoesthesia and strength improved. M-protein and IgM level decreased. In patient 2, already after three cycles, the monoclonal component disappeared and there was dramatic improvement of symptoms and gait normalization. At the end of therapy anti-MAG antibody titer decreased to 5462 BTU. Neurophysiology also improved. CONCLUSIONS In our patients, obinutuzumab was effective as a first-line treatment of anti-MAG antibody polyneuropathy. CLL might have had a role in the response to therapy, but the associations might be considered in future trials.
Collapse
Affiliation(s)
- C Briani
- Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
| | - A Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padova, Italy
| | - A Salvalaggio
- Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
| | | | - L Trentin
- Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padova, Italy
| |
Collapse
|
7
|
Ciscato F, Filadi R, Masgras I, Pizzi M, Marin O, Frezzato F, Trentin L, Pizzo P, Bernardi P, Rasola A. PO-032 Displacement of hexokinase 2 from mitochondria induces mitochondrial Ca2 +overload and caspase-independent cell death in cancer cells. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
8
|
Garrido Castro P, van Roon EHJ, Pinhanços SS, Trentin L, Schneider P, Kerstjens M, Te Kronnie G, Heidenreich O, Pieters R, Stam RW. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis. Leukemia 2018; 32:323-331. [PMID: 28690313 DOI: 10.1038/leu.2017.216] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Revised: 06/21/2017] [Accepted: 06/26/2017] [Indexed: 11/08/2022]
Abstract
MLL-rearranged acute lymphoblastic leukaemia (ALL) represents an aggressive malignancy in infants (<1 year of age), associated with poor outcome. Current treatment intensification is not further possible, and novel therapy strategies are needed. Notably, MLL-rearranged ALL is characterised by a strongly deregulated epigenome and shows sensitivity to epigenetic perturbators. Here we demonstrate the in vivo efficacy of the histone deacetylase inhibitor panobinostat (LBH589) using xenograft mouse models of MLL-rearranged ALL. Panobinostat monotherapy showed strong anti-leukaemic effects, extending survival and reducing overall disease burden. Comprehensive molecular analyses in vitro showed that this anti-leukaemic activity involves depletion of H2B ubiquitination via suppression of the RNF20/RNF40/WAC E3 ligase complex; a pivotal pathway for MLL-rearranged leukaemic maintenance. Knockdown of WAC phenocopied loss of H2B ubiquitination and concomitant cell death induction. These combined data demonstrate that panobinostat cross-inhibits multiple epigenetic pathways, ultimately contributing to its highly efficacious targeting of MLL-rearranged ALL.
Collapse
Affiliation(s)
- P Garrido Castro
- Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - E H J van Roon
- Department of Pediatric Hematology/Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands
| | - S S Pinhanços
- Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - L Trentin
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - P Schneider
- Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - M Kerstjens
- Department of Pediatric Hematology/Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands
| | - G Te Kronnie
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - O Heidenreich
- Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
- North of England Stem Cell Institute, Newcastle and Durham Universities, Newcastle upon Tyne, UK
| | - R Pieters
- Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - R W Stam
- Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
| |
Collapse
|
9
|
Baiardi S, Sciamanna L, Mondini S, Gentili C, Signorelli R, Trentin L, Cirignotta F. 0664 VIDEO MONITORING DURING MAINTENANCE OF WAKEFULNESS TEST: MAY THE BEHAVIOURAL ANALYSIS BE AN ADDITIONAL TOOL FOR RESULTS INTERPRETATION? Sleep 2017. [DOI: 10.1093/sleepj/zsx050.663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Savino AM, Sarno J, Trentin L, Vieri M, Fazio G, Bardini M, Bugarin C, Fossati G, Davis KL, Gaipa G, Izraeli S, Meyer LH, Nolan GP, Biondi A, Te Kronnie G, Palmi C, Cazzaniga G. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Leukemia 2017; 31:2365-2375. [PMID: 28331226 DOI: 10.1038/leu.2017.93] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2016] [Revised: 01/05/2017] [Accepted: 02/06/2017] [Indexed: 12/18/2022]
Abstract
Leukemias bearing CRLF2 and JAK2 gene alterations are characterized by aberrant JAK/STAT signaling and poor prognosis. The HDAC inhibitor givinostat/ITF2357 has been shown to exert anti-neoplastic activity against both systemic juvenile idiopathic arthritis and myeloproliferative neoplasms through inhibition of the JAK/STAT pathway. These findings led us to hypothesize that givinostat might also act against CRLF2-rearranged BCP-ALL, which lack effective therapies. Here, we found that givinostat inhibited proliferation and induced apoptosis of BCP-ALL CRLF2-rearranged cell lines, positive for exon 16 JAK2 mutations. Likewise, givinostat killed primary cells, but not their normal hematopoietic counterparts, from patients carrying CRLF2 rearrangements. At low doses, givinostat downregulated the expression of genes belonging to the JAK/STAT pathway and inhibited STAT5 phosphorylation. In vivo, givinostat significantly reduced engraftment of human blasts in patient-derived xenograft models of CRLF2-positive BCP-ALL. Importantly, givinostat killed ruxolitinib-resistant cells and potentiated the effect of current chemotherapy. Thus, givinostat in combination with conventional chemotherapy may represent an effective therapeutic option for these difficult-to-treat subsets of ALL. Lastly, the selective killing of cancer cells by givinostat may allow the design of reduced intensity regimens in CRLF2-rearranged Down syndrome-associated BCP-ALL patients with an overall benefit in terms of both toxicity and related complications.
Collapse
Affiliation(s)
- A M Savino
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy.,Department of Pediatric Hematology and Oncology, Leukemia Research Section, Edmond and Lily Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.,Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - J Sarno
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
| | - L Trentin
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - M Vieri
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
| | - G Fazio
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
| | - M Bardini
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
| | - C Bugarin
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
| | - G Fossati
- Preclinical R&D Department, Italfarmaco S.p.A., Cinisello Balsamo, Milan, Italy
| | - K L Davis
- Baxter Laboratory in Stem Cell Biology, Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA.,Hematology and Oncology, Department of Pediatrics, Stanford University, Stanford, CA, USA
| | - G Gaipa
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
| | - S Izraeli
- Department of Pediatric Hematology and Oncology, Leukemia Research Section, Edmond and Lily Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.,Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - L H Meyer
- Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany
| | - G P Nolan
- Baxter Laboratory in Stem Cell Biology, Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA.,Hematology and Oncology, Department of Pediatrics, Stanford University, Stanford, CA, USA
| | - A Biondi
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
| | - G Te Kronnie
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - C Palmi
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
| | - G Cazzaniga
- Tettamanti Research Center, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
| |
Collapse
|
11
|
Aina A, Barbero M, Cagnie B, Castelli E, Cook C, Ferrari S, Foglia A, Bizzarri P, Giraudo D, Littlewood C, Pillastrini P, Piscitelli D, Romano M, Tettamanti A, Vanti C, Vercelli S, Voogt L, Maria A, Emanuele S, Paolo P, Francesco S, Antonio C, Ilaria C, Giuseppe O, Raffaele B, Serena F, Alessandro A, Bonfanti M, Pasquetti M, Arianna B, Paolo P, Carla V, Brioschi D, Vitali M, Pedretti A, Fraschini G, Tettamanti A, Castellini G, Gianola S, Bonovas S, Banfi G, Moja L, Castellini G, Gianola S, Frigerio P, Agostini M, Bolotta R, Corbetta D, Gasparini M, Gozzer P, Guariento E, Li L, Pecoraro V, Sirtori V, Turolla A, Andreano A, Moja L, Castellini G, Gianola S, Bonovas S, Moja L, Chiarotto A, Terwee CB, Boers M, Ostelo RW, Chiarotto A, Maxwell LJ, Terwee CB, Wells GA, Tugwell P, Ostelo RW, Chiarotto A, Clijsen R, Fernandez-de-las-Penas C, Barbero M, Matteo C, Sara R, Stefano V, Cislaghi M, Penone G, Marinelli G, Rezzan G, Melegati G, Gatti R, Claudio C, Francesca T, Moriondo A, Stefano V, Doronzio S, Paci M, Ferrari S, Vanti C, Monticone M, Ferrari S, Vanti C, Monticone M, Fabiola G, Anna Z, Serena B, Giorgia C, Francesco S, Ghirlanda F, Schneebeli A, Cescon C, Barbero M, Gioia G, Faccendini S, Aina A, Tettamanti A, Granzotto G, Coppola L, Gava I, Frassinelli M, Gattinoni F, Guidotti L, Postiglione M, Lombardi B, Paci M, Leoni D, Storer D, Gatti R, Egloff M, Barbero M, Tiziano M, Andrea T, Maremmani D, Cencini S, Plebani G, Moresi F, Barbero M, Isnardi M, Gallace A, Cescon C, Gatti R, Moretti N, Maselli, Testa M, Negrini S, Donzelli S, Saveri F, Negrini A, Parzini S, Romano M, Zaina F, Nesi L, Ferrarello F, Bianchi VAM, Paci M, Paci M, Nannetti L, Lombardi B, Mini G, Marchettini M, Ferrarello F, Paci M, Piccolo F, Agosta F, Sarasso E, Adamo P, Temporiti F, Falini A, Gatti R, Filippi M, Piscitelli D, Meroni R, Pellicciari L, Mondelli MA, Favaron T, Cerri CG, Tallarita EA, Elisa R, Stefano V, Sara R, Matteo C, Stefano V, Sarasso E, Agosta F, Tomić A, Basaia S, Dragašević N, Svetel M, Copetti M, Kostic VS, Filippi M, Saveri F, Romano M, Mastrantonio M, Negrini A, Zaina F, Stefano N, Schneebeli A, Castellini G, Redaelli V, Soldini E, Barbero M, Segat M, Casonato O, Margelli M, Pillon S, Spunton V, Fenini R, Garofalo R, Conti M, Valagussa G, Balatti V, Trentin L, Melli S, Norsi M, Grossi E, Vanossi M, Saveri F, Romano M, Vanti C, Taioli S, Gardenghi I, Bertozzi L, Rosso A, Romeo A, Pillastrini P, Vanti C, Ferrari S, Ruggeri M, Monticone M, Vanti C, Filippo B, Conti C, Faresin F, Ruggeri M, Piccarreta R, Ferrari S, Luca V, Stefano V, Claudia V, Joseph CM, Carmen D, Fabrizio P, Youssef S, Montesano M, Picardi M, De Giampaulis P, Corbo M, Pisani L, Anna Z, Fabiola G, Carolina R, Francesco S. 5th National Congress of the Italian Society of Physiotherapy. Arch Physiother 2016. [DOI: 10.1186/s40945-016-0022-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
12
|
Quotti Tubi L, Canovas Nunes S, Brancalion A, Doriguzzi Breatta E, Manni S, Mandato E, Zaffino F, Macaccaro P, Carrino M, Gianesin K, Trentin L, Binotto G, Zambello R, Semenzato G, Gurrieri C, Piazza F. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. Leukemia 2016; 31:292-300. [PMID: 27479180 DOI: 10.1038/leu.2016.209] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Revised: 06/15/2016] [Accepted: 06/21/2016] [Indexed: 12/28/2022]
Abstract
Protein kinase CK2 sustains acute myeloid leukemia cell growth, but its role in leukemia stem cells is largely unknown. Here, we discovered that the CK2 catalytic α and regulatory β subunits are consistently expressed in leukemia stem cells isolated from acute myeloid leukemia patients and cell lines. CK2 inactivation with the selective inhibitor CX-4945 or RNA interference induced an accumulation of leukemia stem cells in the late S-G2-M phases of the cell cycle and triggered late-onset apoptosis. As a result, leukemia stem cells displayed an increased sensitivity to the chemotherapeutic agent doxorubicin. From a molecular standpoint, CK2 blockade was associated with a downmodulation of the stem cell-regulating protein BMI-1 and a marked impairment of AKT, nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) activation, whereas FOXO3a nuclear activity was induced. Notably, combined CK2 and either NF-κB or STAT3 inhibition resulted in a superior cytotoxic effect on leukemia stem cells. This study suggests that CK2 blockade could be a rational approach to minimize the persistence of residual leukemia cells.
Collapse
Affiliation(s)
- L Quotti Tubi
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - S Canovas Nunes
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - A Brancalion
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - E Doriguzzi Breatta
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - S Manni
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - E Mandato
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - F Zaffino
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - P Macaccaro
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - M Carrino
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - K Gianesin
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - L Trentin
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - G Binotto
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
| | - R Zambello
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - G Semenzato
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - C Gurrieri
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| | - F Piazza
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.,Laboratory of Normal and Malignant Hematopoiesis, Venetian Institute of Molecular Medicine, Padova, Italy
| |
Collapse
|
13
|
Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GAM, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J 2016; 6:e404. [PMID: 26967821 PMCID: PMC4817104 DOI: 10.1038/bcj.2016.9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Accepted: 02/02/2016] [Indexed: 11/09/2022] Open
Abstract
Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated on the prospective, multicenter randomized phase-II CLL-009 trial. Interphase cytogenetic and mutational analyses identified TP53 mutations, unmutated IGHV, or del(17p) in 36/96 (37.5%), 68/88 (77.3%) or 22/92 (23.9%) patients. The overall response rate (ORR) was 40.4% (42/104). ORRs were similar irrespective of TP53 mutation (36.1% (13/36) vs 43.3% (26/60) for patients with vs without mutation) or IGHV mutation status (45.0% (9/20) vs 39.1% (27/68)); however, patients with del(17p) had lower ORRs than those without del(17p) (21.7% (5/22) vs 47.1% (33/70); P=0.049). No significant differences in progression-free survival and overall survival (OS) were observed when comparing subgroups defined by the presence or absence of high-risk genetic characteristics. In multivariate analyses, only multiple prior therapies (⩾3 lines) significantly impacted outcomes (median OS: 21.2 months vs not reached; P=0.019). This analysis indicates that lenalidomide is active in patients with relapsed/refractory CLL with unfavorable genetic profiles, including TP53 inactivation or unmutated IGHV. (ClinicalTrials.gov identifier: NCT00963105).
Collapse
Affiliation(s)
- A Bühler
- Department of Internal Medicine III, Ulm University, Ulm, Germany
| | - C-M Wendtner
- Klinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany.,Department I of Internal Medicine, University of Cologne, Cologne, Germany
| | - T J Kipps
- University of California San Diego Moores Cancer Center, La Jolla, CA, USA
| | - L Rassenti
- University of California San Diego Moores Cancer Center, La Jolla, CA, USA
| | - G A M Fraser
- McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada
| | - A-S Michallet
- Hospices civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France
| | - P Hillmen
- St James's Institute of Oncology, Leeds, UK
| | - J Dürig
- University Hospital Essen, Essen, Germany
| | - S A Gregory
- Rush University Medical Center, Chicago, IL, USA
| | | | | | - L Trentin
- Padua University School of Medicine, Padua, Italy
| | - J G Gribben
- Barts Cancer Institute, Queen Mary, University of London, London, UK
| | | | - B Purse
- Celgene Corporation, Summit NJ, USA
| | - J Zhang
- Celgene Corporation, Summit NJ, USA
| | | | - J Mei
- Celgene Corporation, Summit NJ, USA
| | - M Hallek
- Department I of Internal Medicine, University of Cologne, Cologne, Germany.,Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases (CECAD), Cologne, Germany
| | - S Stilgenbauer
- Department of Internal Medicine III, Ulm University, Ulm, Germany
| |
Collapse
|
14
|
Schirmer M, Queudeville M, Trentin L, Eckhoff SM, Meyer LH, Debatin KM. Overcoming apoptosis resistance in high risk acute lymphoblastic leukemia by SMAC mimetics in a preclinical all xenograft model. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1374836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Trentin L, Queudeville M, Eckhoff SM, Hasan N, Debatin KM, Meyer LH. Identification of leukemia initiating cells in pediatric acute lymphoblastic leukemia. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1374841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
16
|
Magni M, Nicola MD, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplant 2014; 49:485-91. [DOI: 10.1038/bmt.2013.214] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Revised: 11/19/2013] [Accepted: 11/19/2013] [Indexed: 11/09/2022]
|
17
|
Hasan MN, Queudeville M, Eckhoff SM, Hermann M, Miller S, Trentin L, Debatin KM, Meyer LH. Preclinical evaluation of a novel treatment strategy to treat high risk ALL. Klin Padiatr 2012. [DOI: 10.1055/s-0032-1310481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Bresolin S, Trentin L, Zecca M, Giordan M, Sainati L, Locatelli F, Basso G, te Kronnie G. Gene expression signatures of pediatric myelodysplastic syndromes are associated with risk of evolution into acute myeloid leukemia. Leukemia 2012; 26:1717-9. [DOI: 10.1038/leu.2012.35] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
19
|
Rota MC, Scaturro M, Fontana S, Foroni M, Boschetto G, Trentin L, Blengio G, Bandettini G, Buratto T, Caporali MG, Napoli C, Ricci ML. Cluster of travel-associated Legionnaires’ disease in Lazise, Italy, July to August 2011. Euro Surveill 2011; 16. [DOI: 10.2807/ese.16.40.19982-en] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Binary file ES_Abstracts_Final_ECDC.txt matches
Collapse
Affiliation(s)
- M C Rota
- National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Rome, Italy
| | - M Scaturro
- Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - S Fontana
- Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - M Foroni
- Service of Hygiene and Public Health, ULSS 22 Bussolengo, Italy
| | - G Boschetto
- Service of Hygiene and Public Health, ULSS 22 Bussolengo, Italy
| | - L Trentin
- Service of Hygiene and Public Health, ULSS 22 Bussolengo, Italy
| | - G Blengio
- Service of Hygiene and Public Health, ULSS 22 Bussolengo, Italy
| | - G Bandettini
- Regional Reference Laboratory for Legionella, Padua, Italy
| | - T Buratto
- Regional Reference Laboratory for Legionella, Padua, Italy
| | - M G Caporali
- National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Rome, Italy
| | - C Napoli
- National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Rome, Italy
| | - M L Ricci
- Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
| |
Collapse
|
20
|
Binotto G, Cillo U, Trentin L, Piazza F, Zaninotto M, Semenzato G, Adami F. Double autologous bone marrow transplantation and orthotopic liver transplantation in a patient with primary light chain (AL) amyloidosis. Amyloid 2011; 18 Suppl 1:132-4. [PMID: 21838461 DOI: 10.3109/13506129.2011.574354049] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- G Binotto
- Department of Clinical & Experimental Medicine, Hematology & Clinical Immunology Section, Padova University School of Medicine, Padova, Italy
| | | | | | | | | | | | | |
Collapse
|
21
|
Mauro FR, Ciolli S, Di Raimondo F, Del Poeta G, Forconi F, Cuneo A, Cortellezzi A, Nobile F, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Orsucci L, Mura MA, Alietti A, Runggaldier EJ, Gamba E, Guarini A, Foa R. A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Cabrelle A, Maschio N, Carraro S, Frezzato F, Binotto G, Gattazzo C, Miorin M, Agostini C, Zambello R, Pandolfi F, Semenzato G, Trentin L. Apoptotic effect of cyclosporin a and dexamethasone in malignant cells of patients with B-chronic lymphocytic leukemia. J BIOL REG HOMEOS AG 2009; 23:239-250. [PMID: 20003763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
B-chronic lymphocytic leukemia (B-CLL) is a malignant disorder characterized by the accumulation of the leukemic cells in the G0-G1 phase of the cell cycle and expressing high levels of the anti-apoptotic protein Bcl-2. Since we observed that the treatment of autoimmune complications with Cyclosporine A (CsA) determined in some CLL patients an improvement not only of the autoimmune phenomena, but also of the leukemic process, we evaluated the in vitro cytotoxicity of CsA as compared to Dexamethasone (Dex) on leukemic cells. Leukemic cells obtained from 32 B-CLL patients showed a heterogeneous pattern of spontaneous apoptosis at 24 h interval and this pattern permitted to identify: Group 1 (14/32) with high (>20%) apoptotic rate and Group 2 (18/32) with low cell death. CsA and Dex increased cell death in both groups with a different timing by an apoptotic mechanism that does not involve Bcl-2. Furthermore, in Group 2, CsA-induced apoptosis was significant higher than that observed with Dex both at 4 and 24 h. We suggest that, in B-CLL, CsA has a significant pro-apoptotic activity manifested also in patients with low spontaneous apoptosis. Our observations might be taken into account to consider new therapeutic strategies in B-CLL.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents/pharmacology
- Apoptosis/drug effects
- Cyclosporine/pharmacology
- Dexamethasone/pharmacology
- Female
- G1 Phase/drug effects
- Gene Expression Regulation, Leukemic/drug effects
- Humans
- Immunosuppressive Agents/pharmacology
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Male
- Middle Aged
- Proto-Oncogene Proteins c-bcl-2/biosynthesis
- Resting Phase, Cell Cycle/drug effects
- Time Factors
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- A Cabrelle
- Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Branch, University of Padua, Padua, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Scquizzato E, Teramo A, Miorin M, Facco M, Piazza F, Noventa F, Trentin L, Agostini C, Zambello R, Semenzato G. Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia 2007; 21:1060-9. [PMID: 17361229 DOI: 10.1038/sj.leu.2404634] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Using polymerase chain reaction (PCR)-based sequence-specific primers, the killer immunoglobulin-like receptor (KIR) genotypes of 35 patients with natural killer (NK)-type lymphoproliferative disease of granular lymphocytes and of 50 normal subjects were investigated to evaluate whether genes coding for activating KIRs were more frequently detected in patients with NK-lymphoproliferative disease of granular lymphocytes (LDGL). Genotype frequency indicated that the most frequently found gene content was eight genes in controls and 14 in patients (P<0.05). The KIR genotype analysis revealed that patient and, surprisingly, control KIR genotypes preferentially consisted of type B haplotypes characterized by the presence of multiple-activating KIRs. Evidence was also provided that the same KIR genotype was shared by a variable number of patients. Interestingly, the recurrent genotypes observed in the patient group were not found in controls. Concerning inhibitory genes, KIR2DL5a and 2DL5b were more frequently detected in patients than in controls (P<0.01), likely representing a discrete feature of the genetic repertoire of the patients. KIR gene repertoire analysis in patients suggests that the susceptibility to NK-LDGL might be related to the presence of activating KIR genes and supports the concept that these receptors may be involved in the priming of granular lymphocytes (GL) proliferation. Population analysis might disclose a genetic background predisposing to this disease.
Collapse
Affiliation(s)
- E Scquizzato
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Branch, Padova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Terrin L, Trentin L, Degan M, Corradini I, Bertorelle R, Carli P, Maschio N, Bo MD, Noventa F, Gattei V, Semenzato G, De Rossi A. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia 2007; 21:965-72. [PMID: 17344921 DOI: 10.1038/sj.leu.2404607] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Activation of telomerase reverse transcriptase (hTERT) is essential for unlimited cell growth and plays a critical role in tumorigenesis. We investigated hTERT gene expression in 134 B-cell chronic lymphocytic leukemia (B-CLL) cases and evaluated its prognostic value with other prognostic markers (IgVH mutation status, CD38 and ZAP-70 expression). Real-time PCR assays to quantify either all hTERT transcripts (AT) or only the full length (FL) transcript encoding the functional protein were developed. hTERT-AT levels strongly correlated with hTERT-FT levels (r=0.743, P<0.0001); both inversely correlated with the percentage of IgVH mutation (P<0.005) and were significantly higher in unmutated than in mutated cases (P=0.004 and P=0.001, respectively). The hTERT values which best discriminated between the unmutated and mutated IgVH cases were 150 and 40 copies for hTERT-AT and hTERT-FL, respectively. Using these cut-off values, there was a significant difference in the survival of patients with high or low hTERT levels (P<0.0001). Unmutated cases with low hTERT levels had an overall survival close to mutated cases with high hTERT levels. Thus, this work identifies hTERT-RNA level as a new prognostic marker in B-CLL, and may be used to identify previously unrecognized patient groups with the same IgVH mutation status and different disease outcomes.
Collapse
Affiliation(s)
- L Terrin
- Section of Oncology, Department of Oncology and Surgical Sciences, University of Padua, Padua, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Minuzzo S, Indraccolo S, Tosello V, Piovan E, Cabrelle A, Trentin L, Semenzato G, Amadori A. CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients. Leukemia 2005; 19:1099-101. [PMID: 15830006 DOI: 10.1038/sj.leu.2403772] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
26
|
|
27
|
Ruvoletto MG, Tono N, Carollo D, Vilei T, Trentin L, Muraca M, Marino M, Gatta A, Fassina G, Pontisso P. Surface expression of squamous cell carcinoma antigen (SCCA) can be increased by the preS1(21-47) sequence of hepatitis B virus. J Gen Virol 2004; 85:621-624. [PMID: 14993646 DOI: 10.1099/vir.0.19130-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
A variant of the serpin squamous cell carcinoma antigen (SCCA) has been identified as a hepatitis B virus binding protein and high expression of SCCA has recently been found in hepatocarcinoma. Since HBV is involved in liver carcinogenesis, experiments were carried out to examine the effect of HBV preS1 envelope protein on SCCA expression. Surface and intracellular staining for SCCA was assessed by FACS analysis. Preincubation of HepG2 cells and primary human hepatocytes with preS1 protein or with preS1(21-47) tetrameric peptide significantly increased the surface expression of SCCA, without modification of its overall cellular burden, suggesting a surface redistribution of the serpin. An increase in HBV binding and internalization was observed after pre-incubation of the cells with preS1 preparations, compared to cells preincubated with medium alone. Pretreatment of cells with DMSO, while not influencing SCCA basal expression, was responsible for an increase in the efficiency of HBV internalization and this effect was additive to that obtained after incubation with preS1 preparations. In conclusion, the HBV preS1(21-47) sequence is able to induce overexpression of SCCA at the cell surface facilitating virus internalization, while the increased efficiency of HBV entry following DMSO addition is not mediated by SCCA.
Collapse
Affiliation(s)
- M G Ruvoletto
- Clinica Medica 5, Università di Padova, via Giustiniani 2, 35128 Padova, Italy
| | - N Tono
- Clinica Medica 5, Università di Padova, via Giustiniani 2, 35128 Padova, Italy
| | - D Carollo
- Immunologia Clinica, Dipartimento di Medicina Clinica e Sperimentale, Università di Padova, via Giustiniani 2, 35128 Padova, Italy
| | - T Vilei
- Clinica Medica 1, Università di Padova, via Giustiniani 2, 35128 Padova, Italy
| | - L Trentin
- Immunologia Clinica, Dipartimento di Medicina Clinica e Sperimentale, Università di Padova, via Giustiniani 2, 35128 Padova, Italy
| | - M Muraca
- Dipartimento di Scienze Mediche e Chirurgiche, Università di Padova, via Giustiniani 2, 35128 Padova, Italy
| | - M Marino
- Xeptagen Spa, via Olivetti, 1 Pozzuoli (Na), Italy
| | - A Gatta
- Clinica Medica 5, Università di Padova, via Giustiniani 2, 35128 Padova, Italy
| | - G Fassina
- Xeptagen Spa, via Olivetti, 1 Pozzuoli (Na), Italy
| | - P Pontisso
- Clinica Medica 5, Università di Padova, via Giustiniani 2, 35128 Padova, Italy
| |
Collapse
|
28
|
Zambello R, Cabrelle A, Trentin L, Agostini C, Semenzato G, Viola A. The raft marker GM1 identifies functional subsets of granular lymphocytes in patients with CD3+ lymphoproliferative disease of granular lymphocytes. Leukemia 2004; 18:771-6. [PMID: 15044927 DOI: 10.1038/sj.leu.2403292] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The raft marker GM1 is expressed at very low levels at the plasma membrane of resting T cells (GM1dull). In vitro T-cell activation induces synthesis of this lipid, which is then expressed at very high levels (GM1bright) at the membrane of activated/effector cells. By flow cytometry and confocal microscopy, we analyzed the expression and organization of GM1 in a series of 15 patients with CD3+ lymphoproliferative disease of granular lymphocytes (LDGL). We found that GM1bright GL were detectable in fresh blood samples obtained in all LDGL patients, although the range of brightly stained cells was extremely variable. This distinctive in vivo pattern has never been shown in T lymphocytes from healthy individuals or in patients with different chronic T or B lymphoproliferative disorders or active infectious diseases. The low number of cycling cells detected in LDGL patients was always included within the GM1bright GL population. Interestingly, GM1bright GL were demonstrated to contain a higher amount of IFN-gamma as compared to GM1dull GL. These findings allow to distinguish subsets of GL at different levels of activation within the monoclonal CD3+ population. The GM1bright GL subset is likely to be responsible for the renewing of GL and thus for maintaining chronic proliferation.
Collapse
Affiliation(s)
- R Zambello
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Clinical Immunology Branch, University of Padua, Italy
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
Ifosfamide (IF) and cyclophosphamide (CTX) are chemotherapeutic agents frequently used in the treatment of human malignancies. These drugs can exhibit a bimodal mechanism of antitumor action with cytotoxic and immunomodulatory effects when associated with adoptive immunotherapy. In human peripheral blood lymphocytes, IF irreversibly inhibits the proliferative response to interleukin-2 in a dose-dependent manner and may also induce the phosphorylation of HSP27 by depleting glutathione. CTX promotes discrete cytokine profiles upregulating the expansion of Th1 cells, and this may be important to increase cellular immune response. The data presented in this report indicate that treatment regimens of CTX and IF may be used according to the tumor immunogenicity.
Collapse
Affiliation(s)
- G Binotto
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Clinical Immunology Branch, Padua, Italy
| | | | | |
Collapse
|
30
|
Abstract
This study is part of the project, "Towards a Pain-Free Hospital," which aims at improving the approach and treatment of the patient in pain. The objective of the study was to evaluate the knowledge and attitudes of doctors and nurses on the wards of a 1000-bed general hospital located in a rather densely-populated, industrialized area of Italy regarding the following topics: attention paid to pain, the use of analgesic drugs, and pain in children. In total, 669 nurses and 225 doctors completed a 16-item questionnaire evaluating knowledge and beliefs about pain. The overall percentage of correct answers was 61% (9.7/16). The score varied among the different wards and ranged from 48% (7.8/16) to 76% (12.3/16). Physicians scored 65% and nurses 59% (p < 0.001). The percentage of correct answers varied widely among the different items (from 30% to 96%). From these results, we conclude that there are still significant knowledge deficits and erroneous beliefs that may hamper treatment of the patient in pain. These results will help in conducting educational programs aimed at improving pain treatment in the different departments of the hospital.
Collapse
Affiliation(s)
- M Visentin
- Unita Operativa di Terapia del Dolore e Cure Palliative, Ospedale S. Bortolo, 36100 Vicenza, Italy
| | | | | | | |
Collapse
|
31
|
Realdon S, Pontisso P, Adami F, Trentin L, Noventa F, Ferrari A, Migliorato I, Gatta A, Alberti A. High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. J Hepatol 2001; 34:723-9. [PMID: 11434619 DOI: 10.1016/s0168-8278(00)00063-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Chronic hepatitis C virus (HCV) infection is associated with a variety of extrahepatic disorders that may relate to direct or indirect effects of virus infection. Increased levels of soluble forms of tumor necrosis factor (TNF) receptors I and II, found in lymphoproliferative and infectious diseases, can interfere with TNF induced apoptotic cell death. The aim of the present study was to evaluate soluble TNF family receptors levels in lymphoproliferative disorders associated with HCV infection. METHODS One hundred and forty-nine subjects were studied, including 120 anti-HCV positive patients (60 without lymphoproliferative manifestations, 47 with type II cryoglobulinemia and 13 with low-grade B-cell non-Hodgkin's lymphoma (B-NHL)) and 29 anti-HCV negative subjects (19 with low-grade B-NHLs and ten normal controls). RESULTS Soluble forms of TNF receptor I, TNF receptor II and Fas were significantly higher in HCV positive patients compared with normal controls. The highest levels were found in patients affected by type II cryoglobulinemia or HCV positive lymphoplasmacytoid lymphomas (LP-NHLs), while HCV positive patients without type II cryoglobulinemia or with other B-NHLs had lower values (P < 0.01). CONCLUSIONS Among HCV infected individuals, very high levels of soluble TNF receptors are significantly associated with type II cryoglobulinemia and LP-NHLs, suggesting that they may be involved in these proliferative disorders.
Collapse
MESH Headings
- Adult
- Aged
- Cryoglobulinemia/blood
- Cryoglobulinemia/virology
- Female
- Genotype
- Hepacivirus/genetics
- Hepatitis C/blood
- Hepatitis C/complications
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/virology
- Lymphoma, B-Cell/blood
- Lymphoma, B-Cell/virology
- Lymphoma, Non-Hodgkin/blood
- Lymphoma, Non-Hodgkin/virology
- Lymphoproliferative Disorders/blood
- Lymphoproliferative Disorders/virology
- Male
- Middle Aged
- Receptors, Tumor Necrosis Factor/blood
- Solubility
- Tumor Necrosis Factor-alpha/metabolism
- fas Receptor/blood
Collapse
Affiliation(s)
- S Realdon
- Clinica Medica 5, Department of Clinical and Experimental Medicine, University of Padova, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M, Binotto G, Valente M, Trentin L, Semenzato G. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001; 158:1703-11. [PMID: 11337368 PMCID: PMC1891930 DOI: 10.1016/s0002-9440(10)64126-0] [Citation(s) in RCA: 165] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The attraction of T lymphocytes into the pulmonary parenchyma represents an essential step in mechanisms ultimately leading to lung allograft rejection. In this study we evaluated whether IP-10 (CXCL10), a chemokine that is induced by interferon-gamma and stimulates the directional migration of activated T cells, plays a role in regulating the trafficking of effector T cells during lung allograft rejection episodes. Immunohistochemical examination showed that areas characterized by acute cellular rejection (grades 1 to 4) and active obliterative bronchiolitis (chronic rejection, Ca) were infiltrated by T cells expressing CXCR3, i.e., the specific receptor for CXCL10. In parallel, T cells accumulating in the bronchoalveolar lavage of lung transplant recipients with rejection episodes were CXCR3+ and exhibited a strong in vitro migratory capability in response to CXCL10. In lung biopsies, CXCL10 was abundantly expressed by graft-infiltrating macrophages and occasionally by epithelial cells. Alveolar macrophages expressed and secreted definite levels of CXCL10 capable of inducing chemotaxis of the CXCR3+ T-cell line 300-19; the secretory capability of alveolar macrophages was up-regulated by preincubation with interferon-gamma. Interestingly, striking levels of CXCR3 ligands could be demonstrated in the fluid component of the bronchoalveolar lavage in individuals with rejection episodes. These data indicate the role of the CXCR3/CXCL10 interactions in the recruitment of lymphocytes at sites of lung rejection and provide a rationale for the use of agents that block the CXCR3/CXCL10 axis in the treatment of lung allograft rejection.
Collapse
Affiliation(s)
- C Agostini
- Department of Clinical and Experimental Medicine, Padua University School of Medicine, Padua, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Ballon G, Trentin L, De Rossi A, Semenzato G. Telomerase activity and clinical progression in chronic lymphoproliferative disorders of B-cell lineage. Leuk Lymphoma 2001; 41:35-45. [PMID: 11342355 DOI: 10.3109/10428190109057952] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The activation of telomerase, which specifically occurs in neoplastic cells to avoid telomere attrition at each cell division, is a necessary event in tumorigenesis. The evidence that telomerase is also present in normal B cells at different levels according to their differentiation and activation state makes the study of telomerase activity in B cell tumors particularly interesting. This review summarizes data concerning telomerase activity in chronic lymphoproliferative disorders of B-cell lineage (B-CLD), making suggestions regarding B-cell development and B-cell tumor histogenesis. The role of telomerase activity as a potential prognostic marker, as well as a target of new antineoplastic strategies is discussed.
Collapse
Affiliation(s)
- G Ballon
- Department of Oncology and Surgical Sciences, Section of Oncology, University of Padova, via Gattamelata 64, 35128 Padova, Italy
| | | | | | | |
Collapse
|
34
|
Agostini C, Siviero M, Facco M, Carollo D, Binotto G, Tosoni A, Cattelan AM, Zambello R, Trentin L, Semenzato G. Antiapoptotic effects of IL-15 on pulmonary Tc1 cells of patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 2001; 163:484-9. [PMID: 11179127 DOI: 10.1164/ajrccm.163.2.2006028] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
In the early phases of human immunodeficiency virus (HIV) disease a T-cell alveolitis sustained by cytotoxic T lymphocytes (CTL) with anti-HIV activity occurs in the lung. With the progression of HIV disease, pulmonary CTL become infected and their cytotoxic activity declines. To investigate the potential causes leading to this phenomenon, we evaluated T cells obtained from the bronchoalveolar lavage (BAL) of 18 HIV-infected patients with T-cell alveolitis. BAL T cells were CD45R0+/CD8+ defined as Tc1 cells because they expressed cytoplasmic interferon gamma (IFN-gamma) and were CXCR3+/IL-12Rbeta2+. Furthermore, they bore the interleukin (IL)- 15 receptor, Fas antigen, and tumor necrosis factor receptor (TNFR) type II. When cultured for 24 h highly purified BAL T cells showed an excessive spontaneous apoptosis; after activation with anti-CD3 or ionomycin, the proportion of T cells undergoing cell death increased. Interestingly, we found a direct relationship between the predisposition to undergo spontaneous apoptosis and the levels of Fas expression by BAL T cells. Alveolar macrophages (AMs) expressed high levels of IL-15 which paralleled the intensity of T-cell infiltration in most patients. The predisposition of CD8 T cells to undergo cell death was downregulated by the incubation with IL-15; the protective effect of the cytokine was dose-dependent. Nonetheless, AMs also expressed proapoptotic molecules, including membrane TNF-alpha (mTNF-alpha). Based on these observations it may be suggested that an excessive, spontaneous, and activation-induced apoptosis of pulmonary lymphocytes may be observed in HIV lung and that AMs are major regulators of T-cell homeostasis.
Collapse
Affiliation(s)
- C Agostini
- Department of Clinical and Experimental Medicine, Padua University School of Medicine, Clinical Immunology Branch, Padua, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Agostini C, Facco M, Siviero M, Carollo D, Galvan S, Cattelan AM, Zambello R, Trentin L, Semenzato G. CXC chemokines IP-10 and mig expression and direct migration of pulmonary CD8+/CXCR3+ T cells in the lungs of patients with HIV infection and T-cell alveolitis. Am J Respir Crit Care Med 2000; 162:1466-73. [PMID: 11029363 DOI: 10.1164/ajrccm.162.4.2003130] [Citation(s) in RCA: 83] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The recruitment of cytotoxic T lymphocytes (CTL) is considered to be the major tool for the clearance of HIV from the lower respiratory tract. In this study we evaluated the pathophysiologic role of two lymphotactic CXC chemokines (IP-10 and Mig) in the lung of HIV-infected patients. These chemokines stimulate the directional migration of activated T cells and interact with a specific receptor (CXC receptor 3, CXCR3). Lymphocytes recovered from the bronchoalveolar lavage (BAL) of HIV-infected patients with high intensity T-cell alveolitis were CD8+ T cells expressing high levels of CXCR3 and IFN-gamma, a phenotype that is characteristic of Tc1 cells. Pulmonary T cells expressing CXCR3 exhibited a high migratory capability in response to IP-10 and Mig. Alveolar macrophages recovered from patients with T-cell alveolitis bore the IFN-gamma-inducible proteins IP-10 and Mig. A positive correlation was demonstrated between IP-10, Mig, and IL-15 expression by alveolar macrophages. Interestingly, macrophages isolated from the lung of HIV-infected patients with T-cell alveolitis secreted definite levels of CXCR3 ligands capable of inducing T-cell chemotaxis. Taken together, our data suggest that chemotactic ligands that bind CXCR3 contribute significantly to the accumulation of HIV-specific CTL in the lung.
Collapse
Affiliation(s)
- C Agostini
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Clinical Immunology Branch, Padua, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Trentin L, Perin A, Siviero M, Piazza F, Facco M, Gurrieri C, Galvan S, Adami F, Agostini C, Pizzolo G, Zambello R, Semenzato G. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation. Cancer 2000; 89:1259-68. [PMID: 11002221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
BACKGROUND B7 family molecules are involved in T-B-cell communications after interaction with their ligands CD28 and CD152. They play a key role in costimulatory mechanisms and during antigen presentation by efficient antigen presenting cells. B7 molecules are usually absent or expressed at low intensity on B lymphocytes from healthy subjects. In this study, the authors addressed the questions of whether B7 molecules are expressed and modulated in vitro on malignant B lymphocytes from patients with chronic lymphoproliferative diseases of B-cell type and whether they are able to trigger allogenic T-cell reactions. METHODS Malignant B cells from the peripheral blood of 32 patients with B-cell chronic lymphocytic leukemia, mantle cell lymphoma, hairy cell leukemia, and its variant form were investigated for the expression of B7 molecules on the cell surface and for the ability to trigger allogenic T lymphocytes in different experimental conditions. RESULTS Flow cytometry analysis demonstrated that freshly isolated malignant B cells express B7 molecules and that their expression may be up-regulated by the in vitro triggering of the CD40 molecule. Furthermore, freshly isolated malignant B cells induce allogenic T-cell proliferation. The in vitro triggering of malignant B lymphocytes by CD40, alone and in combination with interleukin-4, elicits a strong allogenic T-cell proliferation. This T-cell proliferation is related mainly to the presence of B7 molecules on malignant and normal B lymphocytes. CONCLUSIONS These findings indicate that malignant B cells are efficient antigen presenting cells. It might be suggested that vaccination with pulsed malignant B cells themselves or dendritic cells with in vitro preactivated tumor B cells may represent an alternative therapeutic approach in these patients to generate an antilymphoma T-cell response in vivo.
Collapse
MESH Headings
- Adult
- Antibodies/immunology
- Antibodies/pharmacology
- Antigen Presentation/immunology
- Antigen-Presenting Cells/immunology
- Antigen-Presenting Cells/metabolism
- Antigens, CD/biosynthesis
- Antigens, CD/immunology
- B-Lymphocytes/immunology
- B-Lymphocytes/metabolism
- B7-1 Antigen/biosynthesis
- B7-1 Antigen/immunology
- B7-2 Antigen
- CD40 Antigens/immunology
- Female
- Flow Cytometry
- Humans
- Leukemia, Hairy Cell/blood
- Leukemia, Hairy Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Lymphocyte Activation/immunology
- Lymphoma, Mantle-Cell/blood
- Lymphoma, Mantle-Cell/immunology
- Male
- Membrane Glycoproteins/biosynthesis
- Membrane Glycoproteins/immunology
- Middle Aged
- T-Lymphocytes/immunology
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- L Trentin
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Clinical Immunology Branch, Padova, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Zambello R, Trentin L, Facco M, Siviero M, Galvan S, Piazza F, Perin A, Agostini C, Semenzato G. Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. Blood 2000; 96:647-54. [PMID: 10887130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
In 21 patients with lymphoproliferative disease of granular lymphocytes (LDGL), we investigated the expression and the function of molecules belonging to TNF-receptor and TNF-ligand superfamilies (CD30/CD30L; CD40/CD40L; CD27/CD70; Fas [CD95]/FasL[CD95L]). Fourteen patients were characterized by a proliferation of granular lymphocytes (GLs) expressing the CD3(+)CD16(+) phenotype, whereas 7 cases showed the CD3(-)CD16(+) CD56 +/- phenotype. Our data show that both CD3(+) and CD3-GLs are preferentially equipped with CD30, CD40, CD40L, CD70, and CD95 antigens; this pattern is usually associated with the lack of CD27 and CD30L antigens expression. CD95L was demonstrated in the cytoplasm in 14 of 21 cases by flow cytometry, but a definite signal was demonstrated in all cases studied using polymerase chain reaction analysis. On functional grounds, a stimulatory activity on rIL-2 mediated redirected-cytotoxicity against Fcgamma+ P815 targets was demonstrated with anti-CD30, CD40, CD40L, CD70, CD95, and CD95L mAbs, although resting cells were unable to exhibit significant redirected-cell lysis. The addition of anti-CD30, CD30L, CD40, CD40L, CD95, and CD95L mAbs did not show any significant effect on cell proliferation at resting conditions or after rIL-2 stimulation, whereas anti-CD70 mAb mediated cell proliferation in 6 of 10 cases tested. This figure was not related to an increase in apoptotic cells, as investigated by Annexin-V expression. Our data indicate that both CD3(+) and CD3(-) GLs are equipped with different costimulatory antigens, supporting the concept that these cells are in vivo activated and suggesting that these molecules might play a role in the cytotoxic mechanisms of GLs. (Blood. 2000;96:647-654)
Collapse
Affiliation(s)
- R Zambello
- Division of Hematology, Vicenza Hospital, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Trentin L, Visentin M. [The predictive lidocaine test in treatment of neuropathic pain]. Minerva Anestesiol 2000; 66:157-61; discussion 162. [PMID: 10817006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
BACKGROUND In daily practice, the intravenous lidocaine drip has been introduced as a predictive test for subsequent oral treatment with adjuvant drugs (anti-depressants, channel blockers and anti-convulsants). Our aim is the assessment of the correlation between the test response and the effectiveness of the consequent oral drug therapy. METHODS 183 inpatients (central and peripheral neuropathic pain), treated between 1996-1997, were retrospectively checked. The trial was conducted as follows: a VAS reading > 5 was taken; a subsequent continuous i.v. lidocaine drip was given, at a dose of 4 mg/kg, in saline solution; a VAS reading was taken before (VAS 0), every 5 minutes, and at the end of the drip (VAS 1); the results of the drip were to be considered positive where pain relief was > or = 50%; irrespective of test results, all patients were given a different follow-up drug therapy; a VAS reading was taken one month after the drug therapy (VAS 2). RESULTS Eighty-five patients (90%), responders to lidocaine, had a pain relief and 71 patients (85%), no responders to lidocaine, did not have improvement by taking oral drugs. CONCLUSIONS In agreement with a other authors, we also noted that there was a statistically significant correlation between the results obtained and the therapy prescribed; the usefulness of a lidocaine drip as routine procedure to predict the therapeutic response of neuropathic pain to adjuvant analgesics is underlined.
Collapse
Affiliation(s)
- L Trentin
- Servizio di Terapia del Dolore e Cure Palliative, Ospedale S. Bortolo di Vicenza, ASL 6 Veneto
| | | |
Collapse
|
39
|
Trentin L, Ballon G, Ometto L, Perin A, Basso U, Chieco-Bianchi L, Semenzato G, De Rossi A. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol 1999; 106:662-8. [PMID: 10468854 DOI: 10.1046/j.1365-2141.1999.01620.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The progressive shortening of telomeres at each cell division is a key mechanism in controlling cell proliferative capacity. The activation of telomerase, a reverse transcriptase that extends telomere length, potentially leads to unlimited cell proliferation, and is believed to play a critical role in the neoplastic process. High levels of telomerase activity have been demonstrated in almost all solid tumours; however, little data is available concerning its expression in chronic B-cell neoplasms. By using a quantitative polymerase chain reaction-based method we quantified telomerase activity in normal B lymphocytes, and in various B-cell malignancies, including chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and hairy cell leukaemia (HCL). Compared to normal B cells, which expressed very low levels of telomerase activity, malignant cells from most of the patients showed a significant increase in telomerase activity, with highest values observed in HCL samples. Moreover, among the CLL and HCL cases, significantly higher levels of telomerase activity were found in patients with progressive disease at 1 year follow-up versus patients with stable disease. These data suggest that telomerase activity might correlate with disease progression.
Collapse
Affiliation(s)
- L Trentin
- Department of Clinical and Experimental Medicine, Clinical Immunology Branch, University School of Medicine, Padova, Italy
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Agostini C, Trentin L, Perin A, Facco M, Siviero M, Piazza F, Basso U, Adami F, Zambello R, Semenzato G. Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. Am J Physiol 1999; 277:L240-50. [PMID: 10444517 DOI: 10.1152/ajplung.1999.277.2.l240] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The accessory function of antigen-presenting cells depends on the presence of a number of costimulatory molecules, including members of the B7 family (CD80 and CD86) and the CD5 coligand CD72. The aim of this study was to evaluate the regulation of T cell-antigen-presenting cell costimulatory pathways in the lung of patients with a typical Th1-type reaction, i.e., sarcoidosis. Although normal alveolar macrophages (AMs) did not bear or bore low levels of costimulatory molecules, AMs from sarcoid patients with CD4 T-cell alveolitis upmodulated CD80, CD86, and CD72 and expressed high levels of interleukin (IL)-15; lymphocytes accounting for T-cell alveolitis expressed Th1-type cytokines [interferon (IFN)-gamma and/or IL-2] and bore high levels of CD5 and CD28 but not of CD152 molecules. In vitro stimulation of AMs with Th1-related cytokines (IL-15 and IFN-gamma) upregulated the expression of CD80 and CD86 molecules. However, stimulation with IL-15 induced the expression of Th1-type cytokines (IFN-gamma) and CD28 on sarcoid T cells, suggesting a role for this macrophage-derived cytokine in the activation of the sarcoid T-cell pool. The hypothesis that CD80 and CD86 molecules regulate the sarcoid T-cell response was confirmed by the evidence that AMs induced a strong proliferation of T cells that was inhibited by pretreatment with CD80 and CD86 monoclonal antibodies. To account for these data, it is proposed that locally released cytokines provide AMs with accessory properties that contribute to the development of sarcoid T-cell alveolitis.
Collapse
Affiliation(s)
- C Agostini
- Department of Clinical and Experimental Medicine, Padua Hospital, Padua University School of Medicine, 35128 Padua, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Trentin L, Agostini C, Facco M, Piazza F, Perin A, Siviero M, Gurrieri C, Galvan S, Adami F, Zambello R, Semenzato G. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest 1999; 104:115-21. [PMID: 10393705 PMCID: PMC408409 DOI: 10.1172/jci7335] [Citation(s) in RCA: 122] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
B- and T-cell recirculation is crucial for the function of the immune system, with the control of cell migration being mainly mediated by several chemokines and their receptors. In this study, we investigated the expression and function of CXCR3 on normal and malignant B cells from 65 patients with chronic lymphoproliferative disorders (CLDs). Although CXCR3 is lacking on CD5(+) and CD5(-) B cells from healthy subjects, it is expressed on leukemic B lymphocytes from all (31/31) patients with chronic lymphocytic leukemia (CLL). The presence of CXCR3 was heterogeneous in other B-cell disorders, being expressed in 2 of 7 patients with mantle cell lymphoma (MCL), 4 of 12 patients with hairy cell leukemia (HCL), and 11 of 15 patients with other subtypes of non-Hodgkin's lymphomas (NHLs). Chemotaxis assay shows that normal B cells from healthy subjects do not migrate in response to IFN-inducible protein 10 (IP-10) and IFN-gamma-induced monokine (Mig). In contrast, a definite migration in response to IP-10 and Mig has been observed in all malignant B cells from patients with CLL, but not in patients with HCL or MCL (1/7 cases tested). Neoplastic B cells from other NHLs showed a heterogenous pattern. The migration elicited by IP-10 and Mig was inhibited by blocking CXCR3. No effect of IP-10 and Mig chemokines was observed on the cytosolic calcium concentration in malignant B cells. The data reported here demonstrate that CXCR3 is expressed on malignant B cells from CLDs, particularly in patients with CLL, and represents a fully functional receptor involved in chemotaxis of malignant B lymphocytes.
Collapse
MESH Headings
- Adult
- Aged
- B-Lymphocytes/chemistry
- B-Lymphocytes/physiology
- Calcium/metabolism
- Chemokine CXCL10
- Chemokines, CXC/pharmacology
- Chemotaxis, Leukocyte/drug effects
- Chemotaxis, Leukocyte/physiology
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Interferon-gamma/pharmacology
- Leukemia, Hairy Cell/metabolism
- Leukemia, Hairy Cell/pathology
- Lymphoma, B-Cell/metabolism
- Lymphoma, B-Cell/pathology
- Male
- Middle Aged
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Neoplasm Proteins/physiology
- Neoplastic Stem Cells/chemistry
- Neoplastic Stem Cells/physiology
- Receptors, CXCR3
- Receptors, Chemokine/biosynthesis
- Receptors, Chemokine/genetics
- Receptors, Chemokine/physiology
Collapse
Affiliation(s)
- L Trentin
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Clinical Immunology Branch, 35128 Padova, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Trentin L, Imberti L, Zambello R, Sottini A, Raimondi R, Facco M, Cazzavillan S, Bonoldi E, Signorini S, Bacigalupo A, Semenzato G, Rodeghiero F, Primi D. Detection of identical T-cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation. Br J Haematol 1999; 106:119-27. [PMID: 10444174 DOI: 10.1046/j.1365-2141.1999.01512.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Using phenotypic, functional and molecular techniques, this study was performed to compare the complexity of the T-cell receptor repertoire of a bone marrow transplanted patient with that of his HLA-matched related donor, both of whom developed a chronic lymphocytosis sustained by CD3+CD8+CD57+CD16-CD56- granular lymphocytes 3 years after transplantation. Although Southern blot analysis revealed the presence of extra bands in both subjects, thus indicating the presence of at least one clonal T-cell population, the study of the different T-cell receptor Vbeta (TCRBV) usage did not demonstrate discrete overexpression of any TCRBV segments. On the contrary, heteroduplex analysis of TCRBV transcripts suggested the presence of oligoclonal T-cell expansions in the two subjects. Cloning and sequencing studies demonstrated that T-cell clones expressing identical TCRBV chains were expanded both in the donor and in the recipient. Furthermore, clones with similar, but not identical, junctional regions were also found in the two subjects. These data indicate that, at the time of the graft, a few cells with a monoclonal/oligoclonal pattern that were present in the donor were transferred to the recipient, where they may have found the same environmental in vivo conditions and/or the antigenic pressure favouring their abnormal expansion.
Collapse
MESH Headings
- Adult
- Amino Acid Sequence
- Blotting, Southern
- Cell Division
- Clone Cells
- Humans
- Immunoglobulin Variable Region/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Male
- Molecular Sequence Data
- Receptors, Antigen, T-Cell, alpha-beta/genetics
- Tissue Donors
- Transplantation, Homologous
Collapse
Affiliation(s)
- L Trentin
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Clinical Immunology Branch, Padova, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Agostini C, Zambello R, Facco M, Perin A, Piazza F, Siviero M, Basso U, Bortolin M, Trentin L, Semenzato G. CD8 T-cell infiltration in extravascular tissues of patients with human immunodeficiency virus infection. Interleukin-15 upmodulates costimulatory pathways involved in the antigen-presenting cells-T-cell interaction. Blood 1999; 93:1277-86. [PMID: 9949171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023] Open
Abstract
Interleukin (IL)-15 regulates the proliferative activity of the CD8(+) T-cell pool in human immunodeficiency virus (HIV)-infected patients, thereby contributing to the maintenance of the CD8(+) T-cell-mediated immune response against HIV in extravascular tissues, including the lung. However, the effects of IL-15 on antigen-presenting cells (APC) during HIV infection are still unclear. In this study, we evaluated whether IL-15 regulates the macrophage stimulatory pathways governing inflammatory events that take place in the lung of patients with HIV infection. As a first step we evaluated the in vitro effects of IL-15 on lung macrophages retrieved from the respiratory tract of eight normal subjects. Although macrophages from uninfected individuals expressed the IL-15 binding proteins (IL-15Ralpha and the common gammac) at resting conditions, they did not express IL-15 messenger RNA (mRNA). However, a 24-hour stimulation with IL-15 induced the expression of interferon-gamma (IFN-gamma) and IL-15 itself, suggesting a role for this cytokine in the activation of the pulmonary macrophage pool during inflammation. As a confirmation of the role of IL-15 in this setting, at resting conditions, alveolar macrophages of patients with HIV infection and T-cell alveolitis expressed IL-15, IFN-gamma, and IL-15 binding proteins; showed an upmodulation of costimulatory molecules, B7 and CD72, which are involved in the APC of macrophages; and behaved as effective accessory cells because they elicited a strong proliferation of T cells. The accessory effect was inhibited by pretreatment with anti-CD72, anti-B7 (CD80 and CD86), and anti-IL-15 monoclonal antibodies (MoAb). We then investigated the relationship between IL-15 and the expression of costimulatory molecules by macrophages. A 24-hour stimulation of IL-15Ralpha+/gammac+ macrophages with IL-15 upregulated the expression of CD80 and CD86. The evidence that IL-15 upregulates the expression of coligands that favor the contact between T cells and APC, per se, triggers T-cell activation and proliferation and acts as a chemoattractant for T cells, suggests that IL-15 plays a key role in Tc1-mediated defense mechanisms taking place in extravascular tissues of patients with HIV disease.
Collapse
Affiliation(s)
- C Agostini
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Padua Hospital, Padua, Padova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Agostini C, Cassatella M, Zambello R, Trentin L, Gasperini S, Perin A, Piazza F, Siviero M, Facco M, Dziejman M, Chilosi M, Qin S, Luster AD, Semenzato G. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 1998; 161:6413-20. [PMID: 9834133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The accumulation of T cells and monocytes at sites of ongoing inflammation represents the earliest step in the series of events that lead to granuloma formation in sarcoidosis. In this study, we evaluated the pulmonary production of IFN-inducible protein 10 (IP-10), a CXC chemokine that stimulates the directional migration of activated T cells. Striking levels of IP-10 were demonstrated in the bronchoalveolar lavage (BAL) fluid of 24 patients with pulmonary sarcoidosis and lymphocytic alveolitis, as compared with patients with inactive disease or control subjects. A positive correlation was demonstrated between IP-10 levels and the number of sarcoid CD45R0+/CD4+ cells in the BAL. Immunochemistry, performed with an anti-human IP-10 polyclonal Ab in lymph nodes displaying prominent sarcoid granulomas, showed that cells bearing IP-10 were mainly epithelioid cells and CD68+ macrophages located inside granulomatous areas. Macrophages recovered from the BAL of sarcoid patients stained positive for IP-10 protein. Furthermore, alveolar macrophages isolated from sarcoid patients with T cell alveolitis and cultured for 24 h in presence of IFN-gamma secreted definite levels of IP-10 capable of inducing T cell chemiotaxis. Interestingly, alveolar lymphocytes recovered from patients with active sarcoidosis were CD4+ T cells expressing Th1 cytokines (IL-2 and IFN-gamma) and high levels of CXCR3. Taken together, these data suggest the potential role of IP-10 in regulating the migration and activation of T cells toward sites of sarcoid inflammatory process and the consequent granuloma formation.
Collapse
Affiliation(s)
- C Agostini
- Department of Clinical and Experimental Medicine, Padova University School of Medicine, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Meazza R, Basso S, Gaggero A, Detotero D, Trentin L, Pereno R, Azzarone B, Ferrini S. Interleukin (IL)-15 induces survival and proliferation of the growth factor-dependent acute myeloid leukemia M-07e through the IL-2 receptor beta/gamma. Int J Cancer 1998; 78:189-95. [PMID: 9754651 DOI: 10.1002/(sici)1097-0215(19981005)78:2<189::aid-ijc12>3.0.co;2-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We have analyzed the effects of IL-15, a growth factor with IL-2-like properties produced by dendritic and stromal cells, on 3 GM-CSF/IL-3-dependent AML cell lines: M-07e, UT-7 and TF-1. M-07e cells proliferated in response to IL-15, while UT-7 and TF-1 cells failed to respond. In addition, IL-15 supported long-term proliferation of M-07e cells, thus allowing selection of a subline (M-07SB), which displayed an enhanced sensitivity to IL-15. M-07e and M-07SB cells undergo apoptosis following 48-hr growth factor (GM-CSF or IL-15) starvation, as detected by cytofluorimetric analysis and DNA laddering. IL-15 (20 ng/ml) prevented apoptosis in both cell lines. M-07e and M-07SB expressed IL-2R beta, IL-2R gamma, Jak-1 and Jak-3 mRNA, while IL-15R alpha mRNA was undetectable. In contrast, IL-15R alpha was expressed in UT-7 and TF-1 cells, which lacked expression of IL-2R beta mRNA and, in the case of UT-7, also of Jak-3 mRNA. Accordingly, surface IL-2R beta protein was identified only in M-07e and M-07SB cells, by indirect immunofluorescence, while no expression of IL-2R alpha and IL-15R alpha was detected. Anti-IL-2R beta antibodies (10 microg/ml) efficiently blocked (90% inhibition) the proliferation and the anti-apoptotic effect induced by IL-15, while anti-GM-CSFR alpha antibodies had no effect. Anti-IL-2R gamma antibodies were less efficient at proliferation inhibition but synergized with suboptimal concentrations of anti-IL-2R beta antibodies. Our data suggest a role of IL-15 as an anti-apoptotic and mitogenic growth factor for a subset of myeloid leukemias expressing a functional IL-2R beta/gamma complex.
Collapse
Affiliation(s)
- R Meazza
- Istituto Nazionale per la Ricerca sul Cancro, Centro di Biotecnologie Avanzate, Genoa, Italy
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Gasperini S, Zambello R, Agostini C, Trentin L, Tassinari C, Cadrobbi P, Semenzato G, Cassatella MA. Impaired cytokine production by neutrophils isolated from patients with AIDS. AIDS 1998; 12:373-9. [PMID: 9520166 DOI: 10.1097/00002030-199804000-00005] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVES To determine the ability of neutrophils isolated from HIV-seropositive patients to produce proinflammatory cytokines. DESIGN The in vitro responsiveness of polymorphonuclear neutrophils (PMN) and peripheral blood mononuclear cells (PBMC) to lipopolysaccharide (LPS), used in the presence or absence of interferon (IFN)gamma, was determined in 47 HIV-positive patients with advanced stages of virus infection. METHODS Cytokines in cell-free supernatants were measured by enzyme-linked immunosorbent assay or radioimmunoassay. RESULTS Cell-free supernatants from PMN isolated from the peripheral blood of HIV-positive patients and stimulated with LPS contained increased amounts of tumour necrosis factor (TNF)-alpha and interleukin (IL)-8 with respect to supernatants obtained from PMN of normal donors. In contrast, release of IL-1beta and IL-1ra (IL-1 receptor antagonist) in response to LPS, or LPS plus IFNgamma, was found to be lower in PMN from HIV-positive patients than in PMN from controls, but was significant only in the case of IL-1ra. Furthermore, the release of IL-12 induced by LPS or LPS plus IFNgamma did not significantly differ between PMN from HIV-positive patients and healthy donors. Concerning PBMC, the production of TNF-alpha and IL-12 in response to LPS, or LPS plus IFNgamma, was found to be significantly higher in cells isolated from HIV-positive patients, whereas the release of IL-1beta was significantly lower. In the case of IL-8, no statistically significant difference was found between PBMC isolated from HIV-positive patients and healthy donors. CONCLUSIONS Collectively, the data suggest that in HIV-positive patients with advanced stages of disease, the ability of PMN to produce specific cytokines in response to LPS is significantly altered. Alterations in this ability might contribute to the evolution of HIV disease.
Collapse
Affiliation(s)
- S Gasperini
- Department of General Pathology, University of Verona, Italy
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Trentin L, Zambello R, Sancetta R, Facco M, Cerutti A, Perin A, Siviero M, Basso U, Bortolin M, Adami F, Agostini C, Semenzato G. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res 1997; 57:4940-7. [PMID: 9354461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Several costimulatory molecules play a key role in the differentiation of B lymphocytes and in T-B-cell interactions. In this study, we addressed the question of whether different receptors and counter-receptors may be expressed on malignant B lymphocytes from chronic B-cell malignancies. Using flow cytometry and reverse transcription PCR analyses, the expression of molecules belonging to the tumor necrosis factor receptor (TNFR) and tumor necrosis factor ligand (TNFL) families, as well as the expression of CD80 and CD86 molecules, was analyzed in normal B cells and in different chronic lymphoproliferative disorders of B-cell type, including B-cell chronic lymphocytic leukemia (CLL), mantle cell lymphoma, hairy cell leukemia (HCL), and HCL variant. Different patterns of expression of TNFR and TNFL superfamily molecules were demonstrated among B-cell malignancies. In particular, CD40 was commonly observed on all B cells (both tumor and normal), whereas its ligand (CD40L), which is usually undetectable on resting normal B lymphocytes, was expressed in CLL and HCL but not in other chronic lymphoproliferative disorders. CD27 was not shown in normal B cells, although it was present in all malignancies and with particularly high density in mantle cell lymphoma. CD70 was widely distributed on tumor B lymphocytes, but not on the CD5+ normal counterpart. CD30 was strongly expressed in HCL variant and weakly in B-cell CLL, whereas its ligand showed a wide pattern of expression, including all neoplastic and normal B cells. TNFR II (CD120b) and CD80 were distributed on neoplastic B cells from all groups, usually at an intermediate to high degree of intensity, whereas the CD86 molecule was present at lower intensity than CD80. Finally, reverse transcription PCR analysis confirmed the presence of CD40L, CD30, and CD30L mRNAs in those B cells expressing the corresponding membrane-bound proteins at low density. Our data indicate that TNFR and TNFL molecules are of use clinically both in differentiating B-cell malignancies from the normal counterpart (i.e., CD27, CD70, CD40L, CD30, and CD80) and in defining different chronic B-cell disorders (i.e., CD40L, CD27, and CD30). Interestingly, the observation that several receptors and their ligands (i.e., CD40/CD40L, CD30/CD30L, and CD27/CD70) can be expressed on the same cell suggests that these molecules play a role in initiating and maintaining the neoplastic process by mediating B-T and B-B interactions.
Collapse
Affiliation(s)
- L Trentin
- Department of Clinical and Experimental Medicine, Padua University School of Medicine, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Zambello R, Loughran TP, Trentin L, Rassu M, Facco M, Bortolin M, Nash R, Agostini C, Semenzato G. Spontaneous resolution of p58/EB6 antigen restricted NK-type lymphoproliferative disease of granular lymphocytes: role of Epstein Barr virus infection. Br J Haematol 1997; 99:215-21. [PMID: 9359527 DOI: 10.1046/j.1365-2141.1997.3623176.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We describe a patient with a CD3- lymphoproliferative disease of granular lymphocytes (LDGL) characterized by proliferation of CD3-CD16+ GL, restricted to the expression of p58/EB6 antigen and lacking the p58/GL183 antigen. Using PCR analysis we demonstrated the presence of EBV DNA in the peripheral blood mononuclear cells and purified CD16+ GL from the patient; a monoclonal episomic configuration of the virus could not be demonstrated with Southern blot analysis. The presence of EBV DNA was also detected by PCR in the serum; this finding was associated with a serological pattern consistent with a previous, already seroconverted, EBV infection. During a 4-year follow-up the lymphocytosis spontaneously disappeared; interestingly, in terms of the p58 antigen expression, we provided evidence of the reconstitution of a normal pattern of circulating NK subsets (i.e. p58/EB6+ p58/GL183-, p58/EB6+ p58/GL183+, p58/EB6- p58/GL183-, p58/EB6-p58/GL183+). At the time of resolution of lymphocytosis, EBV-PCR analysis still demonstrated the persistence of EBV DNA in peripheral blood mononuclear cells, but not in the patient's serum. By indicating that inciting agents (in this case EBV) are involved in inducing the GL proliferation, our data contribute insights into the pathogenetic mechanisms accounting for in vivo GL accumulation in LDGL. It appears that a second, still unknown, event is required to determine the neoplastic transformation.
Collapse
Affiliation(s)
- R Zambello
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Padova, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Trentin L, Zambello R, Facco M, Sancetta R, Agostini C, Semenzato G. Interleukin-15: a novel cytokine with regulatory properties on normal and neoplastic B lymphocytes. Leuk Lymphoma 1997; 27:35-42. [PMID: 9373194 DOI: 10.3109/10428199709068269] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
IL-15 is a recently discovered cytokine that shares biological activities with IL-2. Although the biological functions displayed by these two molecules overlap to some extent, they are produced by different cell types and bind to distinct receptorial structures. Both cytokines transduce signals through the beta (p75) and gamma (p64) chains of the IL-2R system, but IL-15, like IL-2, binds to its own specific alpha chain, referred to as IL-15Ralpha. Similarly to IL-2, IL-15 is able to trigger both the proliferation and immunoglobulin production by normal B-lymphocytes. These biological functions may be acquired however only when B-cells have been preactivated in vitro with polyclonal mitogens, or alternatively, when they are cultured in association with other stimuli. By contrast, leukemic cells from patients with chronic B-cell malignancies, including B-cell chronic lymphocytic leukemia and hairy cell leukemia, proliferate to IL-15 regardless of in vitro preactivation. This peculiar IL-15 responsiveness distinguishes malignant B-cells from normal B-lymphocytes. Furthermore, the proliferation elicited by IL-15 in B-CLL and HCL is mainly related to the presence of the beta and gamma chains of the IL-2R system on malignant B-lymphocytes.
Collapse
Affiliation(s)
- L Trentin
- Padua University School of Medicine, Department of Clinical and Experimental Medicine, Vicenza Hospital, Padova, Italy
| | | | | | | | | | | |
Collapse
|